Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash Flows from Operating Activities
Net income (loss)	$ (3,688,470)	$ (380,952)
Adjustments to reconcile net income (loss) to net cash used in operations
Gain on derivative liability	140,043	139,951
Non cash interest expense	10,246	97,712
Gain on disposal of Resonate Blends	(69,243)
Loss on acquisition of Emergent Health Corp.	2,806,683
Loss on conversion of convertible debt	32,455
Share professional fees/ compensation	306,985
Depreciation and amortization	1,890	3,004
Changes in operating assets and liabilities
Inventory		45,420
Advances to suppliers
Other receivables		30,000
Accounts payable and accrued expenses	279,672	210,134
Due to related party	(19,505)
Net cash provided by (used in) operating activities	(199,244)	145,269
Cash Flows from Investing Activities
Deposit on acquisition of Pegasus Specialty Vehicles LLC
Net cash provided by (used in) investing activities
Cash Flows from Financing Activities
Proceeds from issuance of secured promissory notes	239,500
Proceeds from issuance of convertible notes
Proceeds from warrant exercise		6,000
Repayment of related party advances		(95,846)
Repayment of convertible notes		(118,800)
Net cash provided by (used in) financing activities	239,500	(208,646)
Net increase (decrease) in cash	40,256	(63,377)
Cash, beginning of period	6,938	64,419
Cash, end of period	47,194	1,042
Supplemental cash flow disclosures
Cash paid for interest
Cash paid for taxes
Non-cash investing and financing activities
Conversion of debt for common stock